Drugs / MenC-TT
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 22 trials | ||||||
| Phase 2 | NCT00135564 | Jan → Jul 2003 | meningococcal infection | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 2 | NCT00135486 | Mar 2002 → Jan 2003 | meningococcal infection | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT00392808 | Jan 2007 → May 2008 | meningococcal infection | Center for Public Health Research | Completed | No outcome recorded |
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT00617760 Comparator | Mar 2008 → Aug 2009 | meningococcal meningitis, pneumococcal infection | Pfizer | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MenC-TT | “previously primed with 3 doses of a MenC vaccine conjugated with CRM197 (MenC-CRM) or with 2 doses of a MenC vaccine conjugated with tetanus toxoid (MenC-TT), were randomized...” PMID 19927040 ↗ Feb 2010 |
| Modality | Vaccine | “MenC-TT (Neisseria meningitidis group C polysaccharide-tetanus toxoid) vaccine” NCT00135486 ↗ |
| Route | Intramuscular | “MenC-TT vaccine (0.5 ml) to be administered in the left thigh muscle” NCT00617760 ↗ |